FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3133677448> ?p ?o ?g. }

• W3133677448 endingPage "1187" @default.
• W3133677448 startingPage "1174" @default.
• W3133677448 abstract "Abstract Intravenous (IV) edaravone is approved as an amyotrophic lateral sclerosis (ALS) treatment. Because IV administration places a burden on patients, development of orally administered ALS treatments is needed. Therefore, 2 phase 1 studies of oral formulations of edaravone in healthy subjects examined the pharmacokinetics (PK), safety, racial differences, and drug‐drug interactions (DDIs) and investigated the dose of the oral formulation considered to be bioequivalent to the approved dose of the IV formulation. Study 1 was a placebo‐controlled, randomized, single‐blind study of single‐ascending‐dose oral edaravone with the dose range of 30 to 300 mg (n = 56). Study 2 was conducted in 2 cohorts (n = 84); the first assessed DDIs with multiple‐dose edaravone 120 mg/day given over 5 or 8 days (coadministered with single‐dose rosuvastatin, sildenafil, or furosemide), and the second evaluated PK and racial (Japanese/White) differences in PK parameters with doses of 100‐mg edaravone. The oral formulation of edaravone was well absorbed, and plasma concentrations of unchanged edaravone increased more than dose proportionally within the dose range of 30 to 300 mg. No effect of race on oral edaravone PK and no notable DDI effects possibly caused by orally administered edaravone were observed. The oral edaravone formulations were safe and tolerable under the assessed conditions. Mathematical modeling determined that equivalent exposures in plasma with the approved dose of the IV edaravone formulation, as reported previously, could be achieved when the oral edaravone formulation was administered at a dose of ≈100 mg, with an absolute bioavailability of ≈60%." @default.
• W3133677448 created "2021-03-15" @default.
• W3133677448 creator A5003376440 @default.
• W3133677448 creator A5021819365 @default.
• W3133677448 creator A5022178037 @default.
• W3133677448 creator A5027981078 @default.
• W3133677448 creator A5042171523 @default.
• W3133677448 creator A5042413392 @default.
• W3133677448 creator A5047488468 @default.
• W3133677448 creator A5052085221 @default.
• W3133677448 creator A5067268545 @default.
• W3133677448 date "2021-03-11" @default.
• W3133677448 modified "2023-10-16" @default.
• W3133677448 title "Evaluation of Pharmacokinetics, Safety, and Drug‐Drug Interactions of an Oral Suspension of Edaravone in Healthy Adults" @default.
• W3133677448 cites W1985410301 @default.
• W3133677448 cites W2067861363 @default.
• W3133677448 cites W2115763439 @default.
• W3133677448 cites W2128167427 @default.
• W3133677448 cites W2324916026 @default.
• W3133677448 cites W2398498214 @default.
• W3133677448 cites W2416750449 @default.
• W3133677448 cites W2616124858 @default.
• W3133677448 cites W2750922690 @default.
• W3133677448 cites W2751686962 @default.
• W3133677448 cites W2751841726 @default.
• W3133677448 cites W2752136277 @default.
• W3133677448 cites W2753425250 @default.
• W3133677448 cites W2753856617 @default.
• W3133677448 cites W2870204682 @default.
• W3133677448 cites W2989931874 @default.
• W3133677448 cites W3034439772 @default.
• W3133677448 cites W3048405075 @default.
• W3133677448 cites W3082727135 @default.
• W3133677448 cites W4248098506 @default.
• W3133677448 cites W4248518818 @default.
• W3133677448 cites W4249220977 @default.
• W3133677448 cites W4252979096 @default.
• W3133677448 cites W4253006777 @default.
• W3133677448 doi "https://doi.org/10.1002/cpdd.925" @default.
• W3133677448 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8518673" @default.
• W3133677448 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33704925" @default.
• W3133677448 hasPublicationYear "2021" @default.
• W3133677448 type Work @default.
• W3133677448 sameAs 3133677448 @default.
• W3133677448 citedByCount "12" @default.
• W3133677448 countsByYear W31336774482021 @default.
• W3133677448 countsByYear W31336774482022 @default.
• W3133677448 countsByYear W31336774482023 @default.
• W3133677448 crossrefType "journal-article" @default.
• W3133677448 hasAuthorship W3133677448A5003376440 @default.
• W3133677448 hasAuthorship W3133677448A5021819365 @default.
• W3133677448 hasAuthorship W3133677448A5022178037 @default.
• W3133677448 hasAuthorship W3133677448A5027981078 @default.
• W3133677448 hasAuthorship W3133677448A5042171523 @default.
• W3133677448 hasAuthorship W3133677448A5042413392 @default.
• W3133677448 hasAuthorship W3133677448A5047488468 @default.
• W3133677448 hasAuthorship W3133677448A5052085221 @default.
• W3133677448 hasAuthorship W3133677448A5067268545 @default.
• W3133677448 hasBestOaLocation W31336774482 @default.
• W3133677448 hasConcept C112705442 @default.
• W3133677448 hasConcept C142724271 @default.
• W3133677448 hasConcept C181389837 @default.
• W3133677448 hasConcept C204787440 @default.
• W3133677448 hasConcept C22979827 @default.
• W3133677448 hasConcept C27081682 @default.
• W3133677448 hasConcept C2777056448 @default.
• W3133677448 hasConcept C2779554857 @default.
• W3133677448 hasConcept C42404028 @default.
• W3133677448 hasConcept C71924100 @default.
• W3133677448 hasConcept C98274493 @default.
• W3133677448 hasConceptScore W3133677448C112705442 @default.
• W3133677448 hasConceptScore W3133677448C142724271 @default.
• W3133677448 hasConceptScore W3133677448C181389837 @default.
• W3133677448 hasConceptScore W3133677448C204787440 @default.
• W3133677448 hasConceptScore W3133677448C22979827 @default.
• W3133677448 hasConceptScore W3133677448C27081682 @default.
• W3133677448 hasConceptScore W3133677448C2777056448 @default.
• W3133677448 hasConceptScore W3133677448C2779554857 @default.
• W3133677448 hasConceptScore W3133677448C42404028 @default.
• W3133677448 hasConceptScore W3133677448C71924100 @default.
• W3133677448 hasConceptScore W3133677448C98274493 @default.
• W3133677448 hasIssue "10" @default.
• W3133677448 hasLocation W31336774481 @default.
• W3133677448 hasLocation W31336774482 @default.
• W3133677448 hasLocation W31336774483 @default.
• W3133677448 hasOpenAccess W3133677448 @default.
• W3133677448 hasPrimaryLocation W31336774481 @default.
• W3133677448 hasRelatedWork W2061323067 @default.
• W3133677448 hasRelatedWork W2349338867 @default.
• W3133677448 hasRelatedWork W2352365100 @default.
• W3133677448 hasRelatedWork W2357364067 @default.
• W3133677448 hasRelatedWork W2362278450 @default.
• W3133677448 hasRelatedWork W2364471871 @default.
• W3133677448 hasRelatedWork W2374069256 @default.
• W3133677448 hasRelatedWork W2385472588 @default.
• W3133677448 hasRelatedWork W2401080248 @default.
• W3133677448 hasRelatedWork W2587902810 @default.
• W3133677448 hasVolume "10" @default.

• next